Adimmune
Taipei, Taiwan· Est.
Taiwanese biotech delivering rapid, adjuvant‑enhanced subunit vaccines for emerging infectious diseases.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $50M
AI Company Overview
Taiwanese biotech delivering rapid, adjuvant‑enhanced subunit vaccines for emerging infectious diseases.
Infectious DiseasesVaccines
Technology Platform
Recombinant protein subunit vaccine platform coupled with a proprietary adjuvant (Adjuvant‑101) that enhances immunogenicity and enables rapid, scalable manufacturing.
Opportunities
Leverage the adjuvant platform to secure licensing deals and expand into emerging infectious disease markets, especially in Asia‑Pacific.
Risk Factors
Regulatory delays, funding constraints for late‑stage trials, and intense competition from larger vaccine developers.
Competitive Landscape
Competes with regional vaccine makers such as Medigen and global firms like CSL; differentiation stems from its proprietary adjuvant and rapid manufacturing capability.